These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 24515101)

  • 1. Lead identification and structure-activity relationships of heteroarylpyrazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists.
    Miah AH; Copley RC; O'Flynn D; Percy JM; Procopiou PA
    Org Biomol Chem; 2014 Mar; 12(11):1779-92. PubMed ID: 24515101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lead identification of benzimidazolone and azabenzimidazolone arylsulfonamides as CC-chemokine receptor 4 (CCR4) antagonists.
    Miah AH; Abas H; Begg M; Marsh BJ; O'Flynn DE; Ford AJ; Percy JM; Procopiou PA; Richards SA; Rumley SA
    Bioorg Med Chem; 2014 Aug; 22(15):4298-311. PubMed ID: 24909677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists.
    Procopiou PA; Barrett JW; Barton NP; Begg M; Clapham D; Copley RC; Ford AJ; Graves RH; Hall DA; Hancock AP; Hill AP; Hobbs H; Hodgson ST; Jumeaux C; Lacroix YM; Miah AH; Morriss KM; Needham D; Sheriff EB; Slack RJ; Smith CE; Sollis SL; Staton H
    J Med Chem; 2013 Mar; 56(5):1946-60. PubMed ID: 23409871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of pyrazolopyrimidine arylsulfonamides as CC-chemokine receptor 4 (CCR4) antagonists.
    Miah AH; Champigny AC; Graves RH; Hodgson ST; Percy JM; Procopiou PA
    Bioorg Med Chem; 2017 Oct; 25(20):5327-5340. PubMed ID: 28801066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecule antagonists of the CC chemokine receptor 4 (CCR4).
    Burdi DF; Chi S; Mattia K; Harrington C; Shi Z; Chen S; Jacutin-Porte S; Bennett R; Carson K; Yin W; Kansra V; Gonzalo JA; Coyle A; Jaffee B; Ocain T; Hodge M; LaRosa G; Harriman G
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3141-5. PubMed ID: 17395464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lead optimisation of the N1 substituent of a novel series of indazole arylsulfonamides as CCR4 antagonists and identification of a candidate for clinical investigation.
    Procopiou PA; Ford AJ; Graves RH; Hall DA; Hodgson ST; Lacroix YM; Needham D; Slack RJ
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2730-3. PubMed ID: 22437117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists.
    Lange JH; Coolen HK; van Stuivenberg HH; Dijksman JA; Herremans AH; Ronken E; Keizer HG; Tipker K; McCreary AC; Veerman W; Wals HC; Stork B; Verveer PC; den Hartog AP; de Jong NM; Adolfs TJ; Hoogendoorn J; Kruse CG
    J Med Chem; 2004 Jan; 47(3):627-43. PubMed ID: 14736243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The discrete role of chlorine substitutions in the conformation and supramolecular architecture of arylsulfonamides.
    Fernandes WB; Aragão AQ; Martins FT; Noda-Perez C; Lariucci C; Napolitano HB
    Acta Crystallogr C; 2011 Jul; 67(Pt 7):o226-9. PubMed ID: 21727630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, SAR and intramolecular hydrogen bonding pattern of 1,3,5-trisubstituted 4,5-dihydropyrazoles as potent cannabinoid CB(1) receptor antagonists.
    Lange JH; van der Neut MA; den Hartog AP; Wals HC; Hoogendoorn J; van Stuivenberg HH; van Vliet BJ; Kruse CG
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1752-7. PubMed ID: 20137935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An intracellular allosteric site for a specific class of antagonists of the CC chemokine G protein-coupled receptors CCR4 and CCR5.
    Andrews G; Jones C; Wreggett KA
    Mol Pharmacol; 2008 Mar; 73(3):855-67. PubMed ID: 18042736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and optimisation of novel sulfonamide, selective vasopressin V1B receptor antagonists.
    Baker J; Bingham M; Blackburn-Munro R; Cai J; Craighead M; Gilfillan R; Goan K; Jaap D; Milne R; Morphy JR; Napier S; Presland J; Spinks G; Thomson F
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3603-7. PubMed ID: 21601454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent CCR4 antagonists: synthesis, evaluation, and docking study of 2,4-diaminoquinazolines.
    Yokoyama K; Ishikawa N; Igarashi S; Kawano N; Masuda N; Hattori K; Miyazaki T; Ogino S; Orita M; Matsumoto Y; Takeuchi M; Ohta M
    Bioorg Med Chem; 2008 Sep; 16(17):7968-74. PubMed ID: 18694645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of aryl sulfonamide-based nonsteroidal mineralocorticoid receptor antagonists.
    Futatsugi K; Piotrowski DW; Casimiro-Garcia A; Robinson S; Sammons M; Loria PM; Banker ME; Petersen DN; Schmidt NJ
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6239-42. PubMed ID: 24157365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure based evolution of a novel series of positive modulators of the AMPA receptor.
    Jamieson C; Maclean JK; Brown CI; Campbell RA; Gillen KJ; Gillespie J; Kazemier B; Kiczun M; Lamont Y; Lyons AJ; Moir EM; Morrow JA; Pantling J; Rankovic Z; Smith L
    Bioorg Med Chem Lett; 2011 Jan; 21(2):805-11. PubMed ID: 21190850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N'-(arylsulfonyl)pyrazoline-1-carboxamidines as novel, neutral 5-hydroxytryptamine 6 receptor (5-HT₆R) antagonists with unique structural features.
    van Loevezijn A; Venhorst J; Iwema Bakker WI; de Korte CG; de Looff W; Verhoog S; van Wees JW; van Hoeve M; van de Woestijne RP; van der Neut MA; Borst AJ; van Dongen MJ; de Bruin NM; Keizer HG; Kruse CG
    J Med Chem; 2011 Oct; 54(20):7030-54. PubMed ID: 21866910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of sulfonamide-pyrazole gamma-secretase inhibitors.
    Mattson MN; Neitzel ML; Quincy DA; Semko CM; Garofalo AW; Keim PS; Konradi AW; Pleiss MA; Sham HL; Brigham EF; Goldbach EG; Zhang H; Sauer JM; Basi GS
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2148-50. PubMed ID: 20206516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent and orally bioavailable CCR4 antagonists: Synthesis and structure-activity relationship study of 2-aminoquinazolines.
    Yokoyama K; Ishikawa N; Igarashi S; Kawano N; Masuda N; Hamaguchi W; Yamasaki S; Koganemaru Y; Hattori K; Miyazaki T; Ogino S; Matsumoto Y; Takeuchi M; Ohta M
    Bioorg Med Chem; 2009 Jan; 17(1):64-73. PubMed ID: 19081254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2,8-Diazaspiro[4.5]decan-8-yl)pyrimidin-4-amine potent CCR4 antagonists capable of inducing receptor endocytosis.
    Shukla L; Ajram LA; Begg M; Evans B; Graves RH; Hodgson ST; Lynn SM; Miah AH; Percy JM; Procopiou PA; Richards SA; Slack RJ
    Eur J Med Chem; 2016 Jun; 115():14-25. PubMed ID: 26991939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arylsulfonamides: a study of the relationship between activity and conformational preferences for a series of factor Xa inhibitors.
    Senger S; Convery MA; Chan C; Watson NS
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5731-5. PubMed ID: 16982192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrazole-based sulfonamide and sulfamides as potent inhibitors of mammalian 15-lipoxygenase.
    Ngu K; Weinstein DS; Liu W; Langevine C; Combs DW; Zhuang S; Chen X; Madsen CS; Harper TW; Ahmad S; Robl JA
    Bioorg Med Chem Lett; 2011 Jul; 21(14):4141-5. PubMed ID: 21696952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.